Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma

The prognosis of patients with advanced hepatocellular carcinoma (HCC) is very poor. The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance. Ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Jilkova, Zuzana Macek, Kuyucu, Ayca Zeybek, Kurma, Keerthi, Ahmad Pour, Séyédéh Tayébéh, Roth, Gaël S., Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Sturm, Nathalie, Marche, Patrice N., Hainaut, Pierre, Decaens, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834253/
https://ncbi.nlm.nih.gov/pubmed/29541403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24298
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados